PENTIXAPHARM
6.2.2020 12:48:05 CET | Business Wire | Press release
PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
Interviews:
“With the renowned expertise of the PentixaPharm team, the company is well positioned to bring the lead-compounds PentixaFor and PentixaTher with an effective clinical development program to the next level. We are thrilled to accompany this venture.”,
says Phillip Eckert, Responsible Programme Manager and Partner at ELSA.
“Scintomics is very excited about this new partnership marking another important milestone towards a strong positioning of PentixaPharm as radiopharmaceutical development specialist” , comments Saskia Kropf, CEO of Scintomics. Prof. Hans-Jürgen Wester, founder of Scintomics, adds: “We are enthusiastic by this round A financing to advance the CXCR4 program. Preclinical and clinical data so far have demonstrated encouraging evidence and good potential for targeted cancer therapies. Now with the experienced development team of PentixaPharm, we are sure to quickly establish this theranostic approach towards meaningful clinical trials.”
“We are delighted that in ELSA we have found a strong financing partner with an outstanding expertise in the radiopharmaceutical field. The proceeds of the series A financing will enable us to bring a new treatment for CNS Lymphoma, up to today a disease with limited treatment options, a little closer to patients in need”, adds Anna Steeger, Co-founder of 1717 LSV GmbH and CEO of PentixaPharm.
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68 Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About ELSA Eckert Life Science Accelerator
ELSA, a subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies, which are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature companies.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalised cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 22:36:00 CET | Press release
Delivered solid top and bottom-line performance & advanced strategic priorities in 2025Launched sale process for the Food Ingredients segmentContinuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improve
Grid Dynamics Accelerates AI Transformation Momentum11.2.2026 22:05:00 CET | Press release
Earns Preferred Vendor Status at a Top-Tier Hyperscaler; 2025 AI Revenue Grew 30% Year-Over-YearKey Takeaways: Achieved Preferred Vendor status with a top-tier hyperscaler, opening up a significantly larger revenue opportunity for Grid Dynamics. In 2025, Grid Dynamics achieved 30% year-over-year AI revenue growth. Partners increasingly rely on Grid Dynamics to deliver next-generation AI capabilities to global clients, supporting continued AI revenue growth. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced it has achieved Preferred Vendor status with one of the major hyperscale cloud providers. This milestone follows a strategic, exhaustive two-year vendor consolidation initiative by the hyperscaler that reduced its service provider ecosystem to a small group. This designation establishes the contractual framework for Grid Dynamics to significantly increase business with this hyperscaler, boosting Gr
Altasciences Announces Chris Perkin Appointed Executive Chairman; Marie-Hélène Raigneau Appointed Chief Executive Officer11.2.2026 21:14:00 CET | Press release
Altasciences announced today that Chris Perkin has been appointed Executive Chairman of the company’s Board of Directors, effective Tuesday, February 24, 2026. Following a leadership transition that has been underway for the past 12 months, Marie-Hélène Raigneau, President of the company since April 2025, has been appointed Chief Executive Officer, also effective Tuesday, February 24, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211203073/en/ From left to right: Chris Perkin, Executive Chairman of the Board (Altasciences), and Marie-Hélène Raigneau, Chief Executive Officer (Altasciences). “Having worked alongside Marie-Hélène for over two decades, I am fully confident in her readiness to guide Altasciences forward with clarity and purpose,” said Chris. “I am happy to be stepping aside after 50 years in drug development, knowing that Altasciences is well-positioned for the future.” Chris joined Altasciences as CEO
Sodali & Co Hires BlackRock Investment Stewardship AI and Data Lead11.2.2026 20:20:00 CET | Press release
Brett Miller to lead the firm’s global AI, data and insight offering Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, is pleased to announce that Brett Miller has joined the firm as Global Head of Data Analytics based in New York. Miller joins from BlackRock where he served as Head of Data Analytics for its Investment Stewardship team. In his new role, Miller will lead Sodali’s global AI and data analytics strategy and embed data-driven insight across the firm’s integrated Shareholder Services, Sustainability, and Strategic Communications offering to help support clients navigate the increasingly complex and interconnected governance, investor, and stakeholder landscape. Miller joins Sodali & Co. at a time when investors are rapidly leveraging data and AI to drive investment and voting decisions. He will lead the buildout of an advanced analytics and technology platform to give clients actionable insight into how their narrative is driving capital flow
Andersen Consulting tilføjer Lighthouse Consultants11.2.2026 20:16:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Lighthouse Consultants, et London-baseret konsulentfirma med speciale i retsmedicinsk regnskab og finansielle undersøgelser. Lighthouse Consultants blev stiftet af administrerende direktør Kingsley Bye og leverer ydelser, der omfatter efterforskning af svindel og økonomisk kriminalitet, undersøgelser af bestikkelse og korruption, analyse af retssager og forsikringskrav, finansiel analyse, risikovurderinger, interne revisioner og compliance-gennemgange samt bæredygtighedsrevisioner. Virksomhedens team af erfarne statsautoriserede revisorer arbejder sammen med advokatfirmaer, formuende privatpersoner, virksomheder og velgørende organisationer med henblik på at løse komplekse tvister, mindske risici og øge gennemsigtigheden i finansielle og operationelle processer. "Ved at integrere vores retsmedicinske og efterforskningsmæssige ekspertise med Andersens globale platform kan vi levere en mere omfattende pakke af ydelser, der imødekommer ku
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom